Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-09-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第四十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the appointment of a new board secretary. It references compliance with regulatory rules and company bylaws but does not contain financial data or detailed management reports. It is related to board/management changes, specifically the appointment of a board secretary. The document length is short and focused on governance and board matters, fitting the category of Board/Management Information (MANG).
2022-09-29 Chinese
关于聘任公司董事会秘书的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a new company board secretary, including details about the individual's qualifications and compliance with relevant regulations. It does not contain financial statements, earnings data, or detailed management discussion. It is focused on a change in the company's board or senior management roles. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a notice of a report publication, so it is not RPA or RNS.
2022-09-29 Chinese
关于参加2022年广东上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event organized by regulatory and industry bodies. It includes details about the event date, platform, and participants from the company's management who will communicate with investors. There is no financial data, no report attached or referenced as being published, and no voting or regulatory filing content. The document focuses on investor communication and company governance topics but does not constitute a formal report or presentation. Given the nature of the announcement and the lack of detailed financial or regulatory content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-09-19 Chinese
关于2022年股票期权激励计划预留授予部分股票期权登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of registration for a reserved grant of stock options under the company's 2022 stock option incentive plan. It details the number of options granted, the grant date, exercise price, allocation among recipients, performance conditions, and accounting impact. It references regulatory compliance with the China Securities Regulatory Commission and Shenzhen Stock Exchange rules. The document is a formal announcement of a stock option grant event, not a full financial report or audit. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not a report publication announcement since it contains substantive details about the stock option grant. The content fits best under Capital/Financing Update (CAP) as it relates to equity incentive plan grants and their registration, which affect the company's capital structure and financing arrangements.
2022-09-19 Chinese
关于 2019 年股票期权激励计划第三个行权期采用自主行权模式的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the exercise period and details of a stock option incentive plan. It includes specifics about the stock option code, exercise price, number of options exercisable, exercise period, and the impact on share capital and financials. The document is relatively short (2371 characters) and is focused on informing shareholders and the market about the stock option exercise arrangements and related disclosures. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is not a regulatory filing or certification letter. The content fits best with a Capital/Financing Update (CAP) as it relates to stock option exercises, which affect the company's capital structure and financing arrangements.
2022-09-09 Chinese
关于 2019 年第二期股票期权激励计划第二个行权期采用自主行权模式的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the exercise of stock options under a specific stock option incentive plan. It includes information about the stock option code, exercise price, number of options exercisable, exercise period, and the impact on the company's share capital and financials. It also discusses the management of funds related to the exercise and tax arrangements. The document is not a full financial report but a specific corporate announcement about stock option exercise arrangements and related disclosures. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or a report publication announcement. The content aligns best with a Capital/Financing Update (CAP) as it relates to changes in capital structure through stock option exercises and financing implications. The document length is 2402 characters, which is relatively short but contains substantive information about capital changes rather than just an announcement of a report publication or a regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2022-09-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.